全球癌症恶病质市场规模、份额、趋势和成长分析报告（2026-2034年）

预计癌症恶病质市场将从 2025 年的 30.5 亿美元成长到 2034 年的 48.7 亿美元，2026 年至 2034 年的复合年增长率为 5.34%。

由于癌症患者数量不断增加，以及人们对恶病质作为癌症严重併发症的认识不断提高，癌症恶病质市场预计将迎来显着增长。癌症恶病质是一种多因素综合征，其特征是体重显着下降、肌肉萎缩和身体机能状态恶化，严重影响患者的生活品质和治疗效果。随着医疗专业人员和研究人员认识到在癌症治疗中解决恶病质问题的重要性，对有效治疗方法和管理策略的需求预计将会增加，从而推动该市场的强劲成长。目前的治疗方案包括旨在改善食慾和肌肉量的营养干预、药物和支持性护理。

此外，对癌症恶病质潜在机制的研究和理解不断深入，正在推动市场创新。识别与恶病质相关的特定生物标记和通路，为开发能够更有效地治疗该疾病的标靶治疗铺平了道路。例如，抗发炎药物和合成代谢类固醇作为潜在治疗方案的研究已引起广泛关注。随着研究的不断深入和对恶病质生物学机制新认识的不断揭示，市场有望进一步扩张，并有望改善患者的治疗效果和生活品质。

此外，癌症治疗中多面向综合方法的重要性日益凸显，也正在重塑癌症恶病质的治疗模式。随着医疗服务提供者越来越认识到将营养支持、物理治疗和心理护理融入癌症治疗方案的重要性，对综合恶病质管理方案的需求预计将会增长。这一趋势在个人化医疗的背景下尤其重要，因为个人化的干预措施可以显着提高癌症治疗的有效性。随着癌症恶病质治疗市场的不断发展，治疗方案的创新组合、对综合患者护理的重视以及持续的研究将在推动未来成长方面发挥关键作用。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球癌症恶病质市场（依治疗方法）

• 市场分析、洞察与预测
• 黄体素
• 皮质类固醇
• 联合治疗
• 其他的

5. 全球癌症恶病质市场依作用机制划分

• 市场分析、洞察与预测
• 食慾刺激剂
• 减重稳定剂
• 其他的

6. 全球癌症恶病质市场（依通路划分）

• 市场分析、洞察与预测
• 医院商店
• 零售药局
• 网路药房

7. 全球癌症恶病质市场（依地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Aeterna Zentaris Inc
  • Alder BioPharmaceuticals Inc
  • Aphios Corporation
  • Eli Lilly And Company
  • GTxInc
  • Helsinn Group
  • Merck & Co. Inc
  • Novartis AG
  • Bristol-Myers Squibb Company
  • XBiotech Inc

The Cancer Cachexia Market size is expected to reach USD 4.87 Billion in 2034 from USD 3.05 Billion (2025) growing at a CAGR of 5.34% during 2026-2034.

The cancer cachexia market is poised for significant growth, driven by the increasing prevalence of cancer and the rising awareness of cachexia as a serious complication associated with the disease. Cancer cachexia is a multifactorial syndrome characterized by severe weight loss, muscle wasting, and a decline in overall health, significantly impacting patients' quality of life and treatment outcomes. As healthcare providers and researchers recognize the importance of addressing cachexia in cancer care, the demand for effective therapies and management strategies is expected to rise, positioning this market for robust expansion. Current treatment options include nutritional interventions, pharmacological agents, and supportive care measures aimed at improving appetite and muscle mass.

Moreover, advancements in research and understanding of the underlying mechanisms of cancer cachexia are driving innovation within the market. The identification of specific biomarkers and pathways involved in cachexia is paving the way for the development of targeted therapies that can more effectively address this condition. For instance, the exploration of anti-inflammatory agents and anabolic steroids is gaining traction as potential treatment options. As research continues to uncover new insights into the biology of cachexia, the market is likely to expand further, driven by the promise of improved patient outcomes and quality of life.

Additionally, the growing emphasis on multidisciplinary approaches to cancer care is shaping the cancer cachexia landscape. As healthcare providers increasingly recognize the importance of integrating nutritional support, physical therapy, and psychological care into cancer treatment plans, the demand for comprehensive cachexia management solutions is likely to increase. This trend is particularly relevant in the context of personalized medicine, where tailored interventions can significantly enhance the effectiveness of cancer therapies. As the cancer cachexia market continues to evolve, the combination of innovative treatment options, a focus on holistic patient care, and ongoing research will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

• Progestogens
• Corticosteroids
• Combination Therapies
• Others

By Mechanism of Action

• Appetite Stimulators
• Weight Loss Stabilizers
• Others

By Distribution Channel

• Hospital Stores
• Retail Pharmacy Stores
• Online Pharmacies

COMPANIES PROFILED

• Aeterna Zentaris Inc, Alder BioPharmaceuticals Inc, Aphios Corporation, Eli Lilly and Company, GTxInc, Helsinn Group, Merck Co Inc, Novartis AG, BristolMyers Squibb Company, XBiotech Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER CACHEXIA MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutics
• 4.2. Progestogens Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Combination Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER CACHEXIA MARKET: BY MECHANISM OF ACTION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mechanism Of Action
• 5.2. Appetite Stimulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Weight Loss Stabilizers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER CACHEXIA MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER CACHEXIA MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutics
  • 7.2.2 By Mechanism Of Action
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutics
  • 7.3.2 By Mechanism Of Action
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutics
  • 7.4.2 By Mechanism Of Action
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutics
  • 7.5.2 By Mechanism Of Action
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutics
  • 7.6.2 By Mechanism Of Action
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER CACHEXIA INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Aeterna Zentaris Inc
  • 9.2.2 Alder BioPharmaceuticals Inc
  • 9.2.3 Aphios Corporation
  • 9.2.4 Eli Lilly And Company
  • 9.2.5 GTxInc
  • 9.2.6 Helsinn Group
  • 9.2.7 Merck & Co. Inc
  • 9.2.8 Novartis AG
  • 9.2.9 Bristol-Myers Squibb Company
  • 9.2.10 XBiotech Inc